primary biliary cholangitis

Gilead pays $4.3B for CymaBay, the biotech that never gave up on liver disease med
Fierce Biotech
Mon, 02/12/24 - 11:53 am
Gilead Sciences
CymaBay Therapeutics
M&A
liver disease
seladelpar
primary biliary cholangitis
Ipsen/Genfit eye June FDA verdict for liver drug elafibranor
Pharmaphorum
Thu, 12/7/23 - 11:01 am
Genfit
Ipsen
elafibranor
primary biliary cholangitis
FDA
priority review
Ipsen and Genfit to file for EMA and FDA approval for elafibranor
Clinical Trials Arena
Fri, 06/30/23 - 10:12 am
Ipsen
Genfit
EMA
FDA
elafibranor
liver disease
primary biliary cholangitis
FDA adds new 'do not use' note to Intercept's Ocaliva label after a slew of side effect reports in cirrhosis patients
Endpoints
Thu, 05/27/21 - 11:06 am
Intercept Pharma
NASH
Ocaliva
FDA
primary biliary cholangitis
Rose-tinted glasses might not save Genkyotex
EP Vantage
Thu, 05/2/19 - 11:10 am
Genkyotex
primary biliary cholangitis
GKT831
clinical trials
GenFit Moves Lead Candidate into Another Phase III Trial with Breakthrough Therapy
BioSpace
Wed, 04/24/19 - 11:58 am
Genfit
breakthrough therapy
FDA
primary biliary cholangitis
elafibranor
Genfit bags FDA breakthrough tag on route to phase 3 in PBC
Fierce Biotech
Thu, 04/18/19 - 10:21 am
Genfit
FDA
primary biliary cholangitis
elafibranor
clinical trials
GenFit gets $135M Nasdaq IPO for NASH, PBC hopes
Fierce Biotech
Wed, 03/27/19 - 10:21 am
Genfit
IPOs
NASH
primary biliary cholangitis
CymaBay Therapeutics Reports Positive Results from Ph II Study of Seladelpar in Patients with Primary Biliary Cholangitis
CP Wire
Tue, 11/13/18 - 10:26 am
CymaBay
seladelpar
primary biliary cholangitis
NASH
CymaBay Therapeutics Reports Positive Results from Ph II Study of Seladelpar in Patients with Primary Biliary Cholangitis
Tue, 11/13/18 - 10:02 am
CymaBay
seladelpar
primary biliary cholangitis
NASH
CymaBay Initiates Ph III Study of Primary Biliary Cholangitis Drug
CP Wire
Tue, 10/30/18 - 11:22 am
CymaBay
primary biliary cholangitis
clinical trials
seladelpar
Intercept Presents Data form Ph III Substudy That Supports Obeticholic Acid’s Ability to Reverse or Stabilize Fibrosis and Cirrhosis in Primary Biliary Cholangitis (PBC) Patients
CP Wire
Fri, 04/13/18 - 01:10 pm
INTERCEPT
primary biliary cholangitis
obeticholic acid
OCA
Intercept Presents Data form Ph III Substudy That Supports Obeticholic Acid’s Ability to Reverse or Stabilize Fibrosis and Cirrhosis in Primary Biliary Cholangitis (PBC) Patients
Fri, 04/13/18 - 12:53 pm
INTERCEPT
primary biliary cholangitis
obeticholic acid
2 Hotly Debated Drugs Due For FDA Decisions Next Week
Investors.com
Sat, 05/21/16 - 12:35 pm
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Intercept Pharma
Ocaliva
liver disease
primary biliary cholangitis